The Hospital Universitario Central de Asturias is seeking suppliers for the provision of exclusive medications, specifically Givosiran and Lumasiran. This contract is valued at approximately €534,939.80 and falls under the health sector. Interested suppliers can find more details and apply through t
Contract awarded. Originally published 1 years ago.
Only 2 prior awards here — too little to read.
In healthcare medical, MANAGEMENT OF THE HEALTH AREA IV OF THE HEALTH SERVICE OF THE PRINCIPALITY OF ASTURIAS has awarded 2 contracts to 2 suppliers.
Across healthcare medical, the most active winners are URTICA SP Z O O, SALUS INTERNATIONAL SP Z O O, URTICA SP Z OO — the field to beat, or your route in as a partner.
This contract involves the supply, installation, and maintenance of three water purification systems for the Central Laboratory of the Central University Hospital of Asturias. The total value of the contract is approximately €397,061.47. The deadline for submitting proposals is November 19, 2025. Th
This contract involves the supply of exclusive pharmaceuticals, specifically Cabotegravir 600 mg, a long-acting injectable suspension. The contract is intended for the Central University Hospital of Asturias. The supplier will provide 1 vial of 3 ml of this medication. The total value of the contrac
This contract opportunity involves the supply of medical materials and equipment for hemofiltration at the Central University Hospital of Asturias. The total value of the contract is approximately €1,071,584.80. Suppliers are invited to provide the necessary goods and services to support the hospita
This contract involves the supply of embolization coils for the Central University Hospital of Asturias. The total value of the contract is €5,846,100. The deadline for submitting bids is July 1, 2025. This opportunity is part of the health sector and is managed by the Health Management Area IV of t
Innovate UK is investing up to £25.4 million to help develop and test early cancer diagnostic technologies, particularly for less common cancers, with projects costing £1.5-£4 million over 24-36 months.
Innovate UK is offering up to £25.4 million to fund collaborative projects that clinically validate innovative early cancer diagnostic technologies and devices led by UK organisations including at least one SME.
UKHSA seeks supplier information for Doxycycline 10-pack supply through a preliminary market engagement exercise under the Procurement Act 2023.
Suppliers are invited to complete a preliminary market engagement questionnaire about patient diagnostic and monitoring electrodes by 21st September 2026 through eTendersNI.
